Trial · NCT04772352
Effects of Febuxostat for Lowering Uric Acid in NAFLD Patients With Gout
NCT04772352, Phase 2, Unknown, Ningbo No. 1 Hospital
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Effects of Febuxostat for Lowering Uric Acid in NAFLD Patients With Gout. Trials, record NCT04772352. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04772352
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Febuxostat for Lowering Uric Acid in NAFLD Patients With Gout
- NCT number
- NCT04772352
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 200 participants, estimated
- Lead sponsor
- Ningbo No. 1 Hospital
- Conditions
- Nonalcoholic Fatty Liver Disease
- Interventions
- febuxostat treatment, lifestyle intervention
- First posted
- 2021-02-26
- Last updated
- 2021-02-26
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Liver fat content of subjects in different groups | at the first week. | Liver fat was assessed based on Magnetic Resonance Imaging (MRI). |
| Primary | Liver fat content of subjects in different groups | at the 24th week . | Liver fat was assessed based on Magnetic Resonance Imaging (MRI). |
| Primary | Liver fat content of subjects in different groups | at the 48th week. | Liver fat was assessed based on Magnetic Resonance Imaging (MRI). |
| Primary | Serum uric acid levels of subjects in different groups | at the first week | blood samples was assessed after 12 hours overnight fasting for the determination of hematological and biochemical variables, which were measured using an automated hematology analyzer by standard methods. |
| Primary | Serum uric acid levels of subjects in different groups | at the forth week. | blood samples was assessed after 12 hours overnight fasting for the determination of hematological and biochemical variables, which were measured using an automated hematology analyzer by standard methods. |
| Primary | Serum uric acid levels of subjects in different groups | at the twelfth week. | blood samples was assessed after 12 hours overnight fasting for the determination of hematological and biochemical variables, which were measured using an automated hematology analyzer by standard methods. |
| Primary | Serum uric acid levels of subjects in different groups | at the 24th week. | blood samples was assessed after 12 hours overnight fasting for the determination of hematological and biochemical variables, which were measured using an automated hematology analyzer by standard methods. |
| Primary | Serum uric acid levels of subjects in different groups | at the 36th week. | blood samples was assessed after 12 hours overnight fasting for the determination of hematological and biochemical variables, which were measured using an automated hematology analyzer by standard methods. |
| Primary | Serum uric acid levels of subjects in different groups | at the 48th week. | blood samples was assessed after 12 hours overnight fasting for the determination of hematological and biochemical variables, which were measured using an automated hematology analyzer by standard methods. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04772352
GET https://conductscience.org/api/trials/v1/NCT04772352/registered